# reload+after+2024-01-22 15:43:59.459652
address1§1220 Concord Avenue
address2§Suite 600
city§Concord
state§CA
zip§94520
country§United States
phone§925 288 6000
website§https://www.cerus.com
industry§Medical Devices
sector§Healthcare
longBusinessSummary§Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
fullTimeEmployees§665
companyOfficers§[{'maxAge': 1, 'name': 'Mr. William M. Greenman', 'age': 56, 'title': 'President, CEO & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 1330155, 'exercisedValue': 627000, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin D. Green', 'age': 51, 'title': 'VP of Finance & CFO', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 748492, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Vivek K. Jayaraman', 'age': 48, 'title': 'Chief Operating Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 861670, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Chrystal  Jensen', 'age': 52, 'title': 'Chief Legal Officer & General Counsel', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 692161, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard J. Benjamin', 'age': 63, 'title': 'Chief Medical Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 719740, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Laurence M. Corash', 'age': 79, 'title': 'Co-Founder & Chief Scientific Officer', 'yearBorn': 1944, 'fiscalYear': 2022, 'totalPay': 697774, 'exercisedValue': 191788, 'unexercisedValue': 1255438}, {'maxAge': 1, 'name': 'Ms. Lori L. Roll', 'title': 'VP of Administration & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthew M. Notarianni', 'title': 'Senior Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Lainie  Corten', 'title': 'Vice President of Global Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alicia  Goodman', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§3
compensationRisk§5
shareHolderRightsRisk§7
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.316
priceToSalesTrailing12Months§2.3116527
currency§USD
dateShortInterest§1702598400
forwardEps§-0.11
exchange§NGM
quoteType§EQUITY
shortName§Cerus Corporation
longName§Cerus Corporation
firstTradeDateEpochUtc§854721000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§986b70aa-e85d-3fdd-978b-d29090a8b43b
gmtOffSetMilliseconds§-18000000
targetHighPrice§6.0
targetLowPrice§2.5
targetMeanPrice§4.13
targetMedianPrice§4.0
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§1.325
grossMargins§0.55312
ebitdaMargins§-0.22554001
trailingPegRatio§None
